Walmart announced it will provide more than 250 medications at no cost to its employees, including GLP-1 drugs, insulin, and inhalers, as part of an expansion of healthcare benefits for its workforce. The new benefit program represents a significant enhancement to employee healthcare coverage at the nation's largest private employer.
Roche's experimental obesity shot enicepatide reduced blood sugar and body weight by 15.5% in type-2 diabetes patients in a mid-stage trial, with a meaningful proportion reaching normalized glucose levels within less than a year of treatment.
Novo Nordisk announced topline results showing CagriSema achieved 12.4% weight loss versus 9.1% for tirzepatide at 60 weeks in adults with type 2 diabetes in the REIMAGINE 5 trial, and induced 21% weight loss at 68 weeks in people with overweight or obesity without diabetes in the REDEFINE trial.
New research shows that GLP-1 receptor agonists like semaglutide, commonly used for weight loss and diabetes treatment, are associated with fewer exacerbations in patients with asthma and chronic obstructive pulmonary disease (COPD). The findings are based on real-world patient data and add to growing evidence of respiratory benefits from these medications.
New research published in The BMJ shows that tirzepatide (Mounjaro), a GLP-1 receptor agonist, reduces the risk of major cardiovascular events by 33% in type 2 diabetes patients with existing heart disease. A separate study also found that consistent medication adherence among diabetes patients reduces heart disease risk by 27%.
A new study shows that tirzepatide (Mounjaro), a GLP-1 receptor agonist drug, reduces heart attack risk by 33% when added to standard care for patients with both type 2 diabetes and existing heart disease. The findings come as worldwide sales of the drug doubled to £13.8 billion in the first half of 2026.
Brazil's health regulator Anvisa approved five new injectable GLP-1 drugs for diabetes and obesity treatment, following expedited regulatory reviews after Ozempic's patent expired in the country in March 2026.
Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adults with HIV, marking the first clinical evidence that the drug may influence human aging beyond its metabolic effects.
Eli Lilly provided its experimental 'triple-G' weight loss drug retatrutide to a 79-year-old patient through the FDA's compassionate use program, marking an extremely rare instance of pre-approval access to an obesity medication.
New research published in JAMA Otolaryngology analyzing health records from nearly 900,000 patients suggests long-term use of GLP-1 drugs like Ozempic and Mounjaro for diabetes management is associated with increased risks of smell and taste disturbances, though experts note these side effects are not common.
Americans are expected to spend more than $1 trillion on prescription drugs in 2026, according to a new report from the American Society of Health-System Pharmacists. The surge is largely attributed to the growing popularity of GLP-1 weight-loss drugs.
Mayo Clinic study finds metabolic and bariatric surgery provides significantly greater long-term cardiovascular risk reduction compared to GLP-1 medications in people with obesity, despite both treatments improving heart health.
New research reveals that approximately 10% of people carry specific genetic variants that make popular diabetes and weight-loss drugs like Ozempic and Wegovy significantly less effective, providing the first genetic explanation for variable drug response.
